24th Oct 2019 12:01
(Alliance News) - Biopharmaceutical firm Motif Bio PLC on Thursday announced a partnership with a US Army-funded institute to investigate iclaprim.
Iclaprim is an antibiotic used against Gram-positive multidrug-resistant bacteria such as MRSA.
London-based Motif Bio will work with the Walter Reed Army Institute of Research, looking into the use of iclaprim to improve the safety and efficacy of antibiotics delivered via aerosol.
The research is being funded via a grant from the US Department of Defense's military infectious diseases research programme, which is looking at the potential of using an aerosol drug-device combination for wound care on the battlefield.
The work will be led by Daniel Zurawski, Motif Bio said.
Motif Bio Chief Medical Officer David Huang said: "When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible.
"The data generated from Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections."
Motif Bio shares were 15% higher in London on Thursday morning at a price of 0.72 pence each.
By George Collard; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
MTFB.L